Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 8912 results

  1. FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)

    This advice has been updated and replaced by NICE healthtech guidance 682.

    Withdrawn advice

  2. Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  3. 3C Patch System for treating diabetic foot ulcers (MIB230)

    This advice has been updated and replaced by NICE Healthtech guidance 615.

    Withdrawn advice

  4. KardiaMobile for the ambulatory detection of atrial fibrillation (MIB232)

    This advice has been updated and replaced by NICE healthtech guidance 606.

    Withdrawn advice

  5. ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections (MIB234)

    This advice has been updated and replaced by NICE healthtech guidance 602.

    Withdrawn advice

  6. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    Discontinued Reference number: GID-TA10598

    Technology appraisal guidance
    Discontinued

  7. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  8. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  9. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    Discontinued Reference number: GID-TA10779

    Technology appraisal guidance
    Discontinued

  10. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    Discontinued Reference number: GID-TA10822

    Technology appraisal guidance
    Discontinued

  11. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Discontinued Reference number: GID-TA11018

    Technology appraisal guidance
    Discontinued

  12. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued Reference number: GID-TA10961

    Technology appraisal guidance
    Discontinued

  13. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    Discontinued Reference number: GID-TA11166

    Technology appraisal guidance
    Discontinued

  14. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

    Technology appraisal guidance
    Discontinued

  15. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    Discontinued Reference number: GID-TA11044

    Technology appraisal guidance
    Discontinued